Editorial: Biological drugs and biosimilars in autoimmune diseasesdoi:10.3389/fphar.2023.1168972AUTOIMMUNE diseasesBIOSIMILARSDRUGSWajda, AnnaPerricone, CarloKashyap, AnniruddhIliyasu, Mahmud YerimaFrontiers in Pharmacology
” said Leah Christl, Ph.D., director of the Therapeutic Biologics and Biosimilars Staff (TBBS) in FDA’s Office of New Drugs, noting that the patents on some widely used biological drugs will expire in the coming years.
Biosimilars and internists Although one of the main expected benefit of the introduction of biosimilar drugs is the reductions in costs and consequently to extend the access to new innovative biotherapeutic drugs, the scientific rules used for defining comparability are the same applied for any already...
FTS Huguet - 《Expert Opinion on Emerging Drugs》 被引量: 0发表: 2017年 Towards Individualized Therapy for Multiple Myeloma -->Keywords: Hematological Malignancy; Multiple Myeloma; Plasma Cell; Targeted Therapies; Immunotherapy; Biological Therapy; Individualized Therapy; Biphosphonates... A Corporation...
Brief introduction:The conference will focus on discovery, development and manufacture of next generation antibody drugs. Welcome to visit Sino Biological at booth 32 or contact us at BD@sinobiological.com Conference:AACR Annual Meeting 2019 Booth:4909 Time:March 29 - April 3, 2019 Location:Georgia...
AB1524EXPLORING THE SAFETY AND EFFECTIVENESS OF BIOSIMILARS BIOLOGICAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS DURING PREGNANCY doi:10.1136/annrheumdis-2024-eular.2861GlucocorticoidsPregnancy and reproductionbiological DMARDBackground: Biosimilar biological disease modifying anti-rheumatic drugs (B-bDMARDs) are ...
Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat. Rev. Drug Discov. 15, 173–183 (2016). Article CAS PubMed PubMed Central Google Scholar Berlin, C. et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell...
An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review Article Open access 12 March 2022 Key Summary Points SB11 has been developed as a ranibizumab biosimilar and approved by the US Food and Drug Administration (FDA) and European Commission (EC). SB11 demons...
Nanoparticle iron medicinal products-Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparat... G Borchard,B Flühmann,S Mühlebach - 《Regulatory Toxicology & Pharmacology Rtp》 被引量: 59发表: 2012年 Health Canada/BIOTECanada ...
GRP-124 Non-Biological Complex Drugs and Their Regulatory Approach - of Concern For Hospital Pharmacists and Medicines Management? Background Intended copies of originator medicinal products (MPs) are categorised as generics or biosimilars (complex large molecular biological MPs) with distinct regulatory ...